These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 33136226)

  • 21. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys.
    Lyras L; Zeng BY; McKenzie G; Pearce RK; Halliwell B; Jenner P
    J Neural Transm (Vienna); 2002; 109(1):53-67. PubMed ID: 11793162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.
    Blandini F; Nappi G; Fancellu R; Mangiagalli A; Samuele A; Riboldazzi G; Calandrella D; Pacchetti C; Bono G; Martignoni E
    J Neural Transm (Vienna); 2003 Aug; 110(8):911-22. PubMed ID: 12898346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone.
    Nissinen E; Lindén IB; Schultz E; Pohto P
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Sep; 346(3):262-6. PubMed ID: 1407012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
    Ferreira JJ; Almeida L; Cunha L; Ticmeanu M; Rosa MM; Januário C; Mitu CE; Coelho M; Correia-Guedes L; Morgadinho A; Nunes T; Wright LC; Falcão A; Sampaio C; Soares-da-Silva P
    Clin Neuropharmacol; 2008; 31(1):2-18. PubMed ID: 18303486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects.
    Vaz-da-Silva M; Loureiro AI; Nunes T; Lopes C; Rocha J; Machado R; Costa R; Torrão L; Falcão A; Wright L; Almeida L; Soares-da-Silva P
    Drugs R D; 2008; 9(6):435-46. PubMed ID: 18989992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism.
    Senek M; Nyholm D; Nielsen EI
    Sci Rep; 2020 Oct; 10(1):18057. PubMed ID: 33093598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome.
    Brusa L; Pierantozzi M; Bassi A; Fedele E; Lunardi G; Giacomini P; Stanzione P
    Neurol Sci; 2004 Jun; 25(2):53-6. PubMed ID: 15221622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique.
    Heikkinen H; Saraheimo M; Antila S; Ottoila P; Pentikäinen PJ
    Eur J Clin Pharmacol; 2001; 56(11):821-6. PubMed ID: 11294372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.
    Müller T; Kolf K; Ander L; Woitalla D; Muhlack S
    Clin Neuropharmacol; 2008; 31(3):134-40. PubMed ID: 18520980
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.
    Napolitano A; Bellini G; Borroni E; Zürcher G; Bonuccelli U
    Parkinsonism Relat Disord; 2003 Jan; 9(3):145-50. PubMed ID: 12573869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erythrocytes catechol-o-methyl transferase activity is up-regulated after a 3-month treatment by entacapone in parkinsonian patients.
    Maltête D; Cottard AM; Mihout B; Costentin J
    Clin Neuropharmacol; 2011; 34(1):21-3. PubMed ID: 21164341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bimodal administration of entacapone in Parkinson's disease patients improves motor control.
    Bet L; Bareggi SR; Pacei F; Bondiolotti G; Meola G; Schapira AH
    Eur J Neurol; 2008 Mar; 15(3):268-73. PubMed ID: 18290846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients.
    Nevrly M; Kanovsky P; Vranova H; Langova K; Hlustik P
    Neurol Sci; 2010 Oct; 31(5):565-9. PubMed ID: 20464572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers.
    Kaakkola S; Gordin A; Järvinen M; Wikberg T; Schultz E; Nissinen E; Pentikäinen PJ; Rita H
    Clin Neuropharmacol; 1990 Oct; 13(5):436-47. PubMed ID: 2272023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers.
    Ahtila S; Kaakkola S; Gordin A; Korpela K; Heinävaara S; Karlsson M; Wikberg T; Tuomainen P; Männistö PT
    Clin Neuropharmacol; 1995 Feb; 18(1):46-57. PubMed ID: 8665534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
    Piccini P; Brooks DJ; Korpela K; Pavese N; Karlsson M; Gordin A
    J Neurol Neurosurg Psychiatry; 2000 May; 68(5):589-94. PubMed ID: 10766888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.
    Hamaue N; Ogata A; Terado M; Tsuchida S; Yabe I; Sasaki H; Hirafuji M; Togashi H; Aoki T
    Brain Res; 2010 Jan; 1309():110-5. PubMed ID: 19879254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimization of oral entacapone administration in patients undergoing levodopa-carbidopa intestinal gel treatment.
    Miyaue N; Ito Y; Yamanishi Y; Tada S; Ando R; Yabe H; Nagai M
    J Neurol Sci; 2024 Feb; 457():122901. PubMed ID: 38280299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
    Brannan T; Prikhojan A; Yahr MD
    J Neural Transm (Vienna); 1997; 104(1):77-87. PubMed ID: 9085195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.